Minimal residual disease by metaphase FISH in children with ALL: clonal cells during or after chemotherapy may not predict relapse.

[1]  W. Hiddemann,et al.  Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. , 2000, Blood.

[2]  H. Gadner,et al.  Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. , 2000, Blood.

[3]  L. Foroni,et al.  INVESTIGATION OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD AND ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA BY MOLECULAR ANALYSIS , 1999, British journal of haematology.

[4]  M. Kami,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[5]  G. Gustafsson,et al.  Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non‐high‐risk patients: the Nordic experience of 2648 patients diagnosed between 1981 and 1996 , 1998, Acta paediatrica.

[6]  H. Cavé,et al.  Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .

[7]  Z. Estrov,et al.  The clinical significance of detection of residual disease in childhood ALL. , 1998, Critical reviews in oncology/hematology.

[8]  Elaine Coustan-Smith,et al.  Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia , 1998, The Lancet.

[9]  H. Sather,et al.  Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T‐cell phenotype or other poor prognostic features , 1998, Cancer.

[10]  S. Richards,et al.  Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X , 1997, British journal of haematology.

[11]  S. Knuutila,et al.  Follow-up of residual disease using metaphase-FISH in patients with acute lymphoblastic leukemia in remission , 1997, Leukemia.

[12]  D. Johnston,et al.  Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. , 1997, The New England journal of medicine.

[13]  P. Zhu,et al.  Detection of minimal residual disease in childhood acute lymphoblastic leukemia after termination of therapy. , 1996, Pediatric hematology and oncology.

[14]  S. Knuutila,et al.  Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia: a metaphase‐FISH study , 1996, British journal of haematology.

[15]  D. Montagna,et al.  Identification of HLA-unrestricted CD8+/CD28- cytotoxic T-cell clones specific for leukemic blasts in children with acute leukemia. , 1995, Cancer research.

[16]  K. Bradstock,et al.  Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. , 1995, Leukemia & lymphoma.

[17]  J. Goldman,et al.  Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. , 1994, Bone marrow transplantation.

[18]  P. Martiat,et al.  Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction. , 1993, Blood.

[19]  J. Rowley,et al.  Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. , 1993, Blood.

[20]  C. Pui.  Acute lymphoblastic leukemia in children. , 2000, Current opinion in oncology.